NEW YORK, Feb. 9 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. , a medical technology company testing its proprietary treatment system for primary and metastatic ...
Retrospective Study by University Hospital Southampton in metastatic uveal melanoma (mUM) patients with liver dominant disease shows hepatic disease control rate of 88.9%, hepatic response rate of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback